As part of the Company’s growth strategy, it is planning to list on the Nasdaq or Euronext stock exchange during 2026.

The aim is to broaden the international capital base, increase visibility in relation to industrial players and establish a platform for long-term value creation. A stock market listing creates the conditions for the continued financing of clinical development, as well as enabling new strategic collaborations and licence agreements at an early stage.

Given Edvince’s modular structure with separate subsidiaries, a stock market listing also means that the Company can gradually realise value – for example through future separate listings or the distribution of individual subsidiaries. This creates a scalable and capital-efficient model for drug development, where each project is given the opportunity to reach its full commercial potential with clear financial transparency for investors.